| http://www.w3.org/ns/prov#value | - The first is a collaboration which includes co-developing and co-commercializing five compounds, four of these are antibodies and the fifth is actually a small molecule MET inhibitor for the treatment of gastric cancer, and gastric cancer by the way there is a tremendous amount of unmet need in many of the Asian markets including Japan towards this particular indication.
|
